Theragenics soars on private takeover offer
This article was originally published in Clinica
Prostate cancer treatment specialist Theragenics’ share price has climbed 36% after it reported it has received a sweetened bid from private equity firm Juniper Investment. The offer of $2.25-2.30 per share, or $69.9-71.4 million in total, is an increase on the $2.05-2.10 per share that Juniper originally proposed on 10 May. Theragenics has agreed to negotiate exclusively with Juniper until 11 June.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.